Compare ARRY & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARRY | NBTX |
|---|---|---|
| Founded | 1989 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2020 | 2018 |
| Metric | ARRY | NBTX |
|---|---|---|
| Price | $6.93 | $33.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 1 |
| Target Price | $10.24 | ★ $26.00 |
| AVG Volume (30 Days) | ★ 6.6M | 39.7K |
| Earning Date | 06-02-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.56 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,284,141,000.00 | N/A |
| Revenue This Year | $16.03 | N/A |
| Revenue Next Year | $7.79 | $11.73 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 40.22 | N/A |
| 52 Week Low | $3.76 | $2.99 |
| 52 Week High | $12.23 | $41.89 |
| Indicator | ARRY | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 33.08 | 57.18 |
| Support Level | $6.47 | $20.11 |
| Resistance Level | $10.02 | N/A |
| Average True Range (ATR) | 0.56 | 2.69 |
| MACD | -0.16 | 0.03 |
| Stochastic Oscillator | 7.54 | 47.72 |
Array Technologies Inc manufacturer of ground-mounting systems used in solar energy projects. The company's segments include: the Array legacy operating segment (Array Legacy Operations) and the STI Operations operating segment (STI Operations). It derives maximum revenue from the Array legacy operating segment. Its product is an integrated system of steel supports, electric motors, gearboxes, and electronic controllers referred to as a single-axis tracker that moves solar panels throughout the day to maintain an optimal orientation to the sun, which increases their energy production. Geographically, the company's operations are in the United States, Australia, Spain, Brazil, and the rest of the world, with the United States deriving the majority of the revenue.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.